ARTICLE | Finance
Bye-bye, build-to-buy
Why Versant is moving away from the build-to-buy model
November 2, 2018 11:28 PM UTC
As another Inception Sciences Inc. company secures an exit, Versant Ventures plans to move away from its build-to-buy model to focus on creating stand-alone companies with broader portfolios and investor syndicates.
On Oct. 31, Ophthotech Corp. (NASDAQ:OPHT) acquired Inception 4 Inc., gaining small molecule inhibitors of HtrA serine peptidase 1 (HTRA1) to treat age-related retinal diseases, including dry age-related macular degeneration (AMD). Ophthotech plans to submit an IND for its lead HTRA1 inhibitor in late 2020...